Two new studies provide robust epidemiological evidence and a mechanistic link, with potential implications for strategies that target Epstein–Barr virus.
Your institute does not have access to this article
Subscription info for Chinese customers
We have a dedicated website for our Chinese customers. Please go to naturechina.com to subscribe to this journal.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Banwell, B. et al. Lancet Neurol. 10, 436–445 (2011).
Bar-Or, A. et al. Trends Mol. Med. 26, 296–310 (2020).
Nourbakhsh, B. et al. Ann. Neurol. 89, 1234–1239 (2021).
Goodin, D. S. Med Res Arch 9, 29 (2021).
Veroni, C. & Aloisi, F. Front. Immunol. 12, 665718 (2021).
Bjornevik, K. et al. Science 375, 296–301 (2022).
Lanz, T. V. et al. Nature 603, 321–327 (2022).
Levin, L. I., Munger, K. L., O’Reilly, E. J., Falk, K. I. & Ascherio, A. Ann. Neurol. 67, 824–830 (2010).
Soldan, S. S. & Lieberman, P. M. Drug Discov. Today Dis. Models 32, 35–52 (2020).
Cencioni, M. T., Mattoscio, M., Magliozzi, R., Bar-Or, A. & Muraro, P. A. Nat. Rev. Neurol. 17, 399–414 (2021).
Lassmann, H., Niedobitek, G., Aloisi, F. & Middeldorp, J. M. Brain 134, 2772–2786 (2011).
Messick, T. E. et al. Sci. Transl. Med. 11, 5612 (2019).
A.B.-O. has participated as a speaker in meetings sponsored by and has received consulting fees from Accure, Atara Biotherapeutics, Biogen, BMS/Celgene/Receptos, GlaxoSmithKline, Gossamer, Janssen/Actelion, Medimmune, Merck/EMD Serono, Novartis, Roche/Genentech and Sanofi-Genzyme, and has received grant support to the University of Pennsylvania from Biogen Idec, Roche/Genentech, Merck/EMD Serono and Novartis.
About this article
Cite this article
Bar-Or, A., Banwell, B., Berger, J.R. et al. Guilty by association: Epstein–Barr virus in multiple sclerosis. Nat Med 28, 904–906 (2022). https://doi.org/10.1038/s41591-022-01823-1
Nature Reviews Microbiology (2022)